GERN - Geron Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.89
DETAILS
HIGH:
$8.00
LOW:
$4.00
MEDIAN:
$6.00
CONSENSUS:
$5.89
UPSIDE:
309.03%
About Geron Corporation (https://www.geron.com)
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | 1967 | $1,001,052 USD |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 1967 | $810,552 USD |
| Harout Semerjian | Chief Executive Officer, President & Director | 1970 | $526,355 USD |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | 1977 | $485,317 USD |
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | 1981 | $307,934 USD |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | – | – |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | – | – |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | – | – |
| Shannon Odam | Executive Vice President & Chief People Officer | 1975 | – |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | – | – |